Are SARMs Legal? What You Need to Know Before You Buy

What Does "Legal" Actually Mean for SARMs in the United States?

SARMs sit in a complicated regulatory position. They are not scheduled controlled substances under the Controlled Substances Act as of mid-2025, but federal law still prohibits selling them as dietary supplements or as unapproved drugs for human use. The FDA has issued more than 25 warning letters to companies marketing SARMs since 2017, repeatedly stating that these compounds do not qualify as dietary ingredients under the Dietary Supplement Health and Education Act (DSHEA) of 1994.

The FDA's position, stated plainly in a 2019 consumer advisory, is that SARMs "have not been approved by FDA and are associated with serious safety concerns, including potential to increase the risk of heart attack or stroke and life-threatening reactions like liver damage." [1] Selling them for human consumption therefore constitutes marketing an unapproved new drug, which violates the Federal Food, Drug, and Cosmetic Act.

The Designer Anabolic Steroid Control Act (DASCA) of 2014 gave the DEA authority to schedule new anabolic steroids quickly. Congress has twice introduced the SARMs Control Act (2018 and 2020) to add SARMs to Schedule III explicitly, but neither bill passed. Personal possession for research or personal use remains a gray area under federal law. State laws vary. [2]

Bottom line for consumers: buying SARMs labeled "for research use only" from an online vendor does not protect you legally or medically. The label is a liability shield for the seller, not a safety certification for the buyer.

Do SARMs Actually Build Muscle? What the Clinical Data Shows

SARMs do produce measurable lean-mass gains in controlled trials, but the effect sizes are modest and no compound has completed Phase III development. The clinical picture is more nuanced than most fitness forums suggest.

Ostarine (MK-2866, enobosarm) is the most studied SARM. A Phase II randomized controlled trial published in the Journal of Cachexia, Sarcopenia and Muscle (Dobs et al., N=159, cancer patients) found that 3 mg/day of enobosarm for 16 weeks produced a statistically significant 1.5 kg increase in lean body mass compared to placebo (P<0.001). [3] GTx Inc. subsequently ran two Phase III trials (POWER 1 and POWER 2, combined N=635) in non-small cell lung cancer patients. Neither met its primary endpoint of stair-climbing power at the pre-specified significance threshold. The drug has not received FDA approval. [4]

Ligandrol (LGD-4033) was studied in a Phase I dose-escalation trial at Boston Medical Center (Basaria et al., 2013, N=76 healthy men). At 1 mg/day for 21 days, lean body mass increased by 1.21 kg vs. 0.03 kg placebo (P<0.001). Strength on leg press increased. Dose-dependent suppression of total testosterone and sex hormone-binding globulin (SHBG) was also documented. [5] RAD-140 and Andarine (S-4) have only preclinical and small Phase I data as of 2025.

The HealthRX medical team uses the following framework when patients ask about SARMs for body recomposition:

HealthRX SARM Evidence Tier Framework

| Compound | Highest Evidence Level | Peak Lean Mass Gain (Human Trial) | HPG Suppression Documented | |---|---|---|---| | Ostarine (MK-2866) | Phase III (failed) | 1.5 kg at 3 mg x 16 wk | Yes | | Ligandrol (LGD-4033) | Phase I | 1.21 kg at 1 mg x 21 days | Yes | | RAD-140 | Preclinical + Phase I | Not established | Yes | | Andarine (S-4) | Preclinical | Not established | Probable |

Contrast these gains with what a supervised testosterone replacement protocol produces. In a landmark NEJM trial (Bhasin et al., 1996, N=43), testosterone enanthate 600 mg/week for 10 weeks increased fat-free mass by 6.1 kg in men who also trained, versus 2.0 kg with training alone and placebo. [6] The SARM gains in clinical trials are real but substantially smaller, and the long-term safety data that guided testosterone's clinical use simply does not exist for SARMs.

Do SARMs Suppress Testosterone and Require PCT?

Yes. Suppression of the hypothalamic-pituitary-gonadal (HPG) axis is one of the best-documented effects of SARMs. The Basaria Phase I LGD-4033 trial showed free testosterone fell by 55% from baseline at the 1 mg dose at day 21. [5] Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) fell proportionally.

After stopping SARMs, most trial participants recovered baseline hormone levels within 5 weeks without intervention. However, that recovery was in healthy young men taking low doses for 21 days. Anecdotal reports from bodybuilding communities describe prolonged suppression after higher, longer cycles, and at least one published case report described a 32-year-old man requiring clomiphene citrate 50 mg/day for 8 weeks to restore testosterone above 300 ng/dL after a 12-week ostarine cycle. [7]

Post-cycle therapy (PCT) with selective estrogen receptor modulators (SERMs) such as clomiphene (Clomid) or tamoxifen (Nolvadex) is commonly used by SARM users, mirroring practice after anabolic steroid cycles. Neither drug is FDA-approved for this indication, but both have established pharmacology for stimulating LH and FSH release. A physician-supervised testosterone panel drawn 4 weeks after stopping a SARM cycle will tell you whether spontaneous recovery is occurring or whether clinical intervention is warranted.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend against the use of androgens in any man who is interested in future fertility." [8] That principle applies to SARMs as well, given their documented HPG axis effects.

Is Anavar Safer Than SARMs or Other Anabolic Steroids?

Anavar (oxandrolone) is a Schedule III controlled substance in the United States, meaning it requires a prescription and has accepted medical uses. Those uses include HIV-associated wasting, severe burns, and constitutional short stature in boys. Because it requires medical supervision by law, patients using it through a legitimate prescription receive baseline bloodwork, dose titration, and monitoring. SARMs carry no such regulatory structure.

Oxandrolone has a relatively favorable hepatic safety profile compared to oral 17-alpha-alkylated steroids like stanozolol. A review in Drug Safety notes that oxandrolone is associated with mild, generally reversible elevations in liver transaminases at therapeutic doses (5 to 20 mg/day). [9] However, "relatively safer" does not mean safe. Virilization in women, lipid abnormalities (HDL reductions averaging 20-30% in some trials), and HPG axis suppression all occur with oxandrolone.

SARMs were designed to separate anabolic effects from androgenic side effects by targeting androgen receptors in muscle and bone selectively, avoiding the prostate and other androgen-sensitive tissues. The selectivity works in animal models. In humans, that selectivity is partial at best. The FDA's 2019 warning noted liver toxicity, stroke risk, and psychiatric effects based on voluntary adverse event reports. Without Phase III data and post-marketing surveillance, the comparative safety of SARMs versus oxandrolone cannot be established with confidence.

For patients seeking body recomposition under physician supervision at HealthRX, the medically defensible options remain FDA-approved agents: testosterone where hypogonadism is confirmed, oxandrolone under the narrow indications above, and GLP-1 receptor agonists for fat mass reduction.

Will SARMs Show Up on a Drug Test?

Yes, with high probability, particularly in WADA-regulated competition testing. SARMs are explicitly listed on the WADA 2024 Prohibited List under Section S1.2 (Other Anabolic Agents). WADA has prohibited SARMs since 2008. [10]

Detection methods have advanced considerably. High-resolution mass spectrometry can identify SARM metabolites in urine for 7 to 28 days after the last dose, depending on the specific compound, the dose, and the individual's metabolism. Ligandrol metabolites have been detected up to 22 days post-dose in a controlled administration study. Ostarine metabolites are detectable for approximately 9 to 16 days at doses as low as 1 mg. [11]

Several high-profile doping cases have involved SARMs inadvertently ingested through contaminated supplements. A 2015 analysis published in JAMA found that 24 out of 44 tested supplements labeled as SARMs contained either a different SARM than labeled, an unapproved drug, or no active ingredient at all. That contamination risk matters for athletes who are not intentionally using SARMs but purchase other supplements from vendors who also handle these compounds. [12]

Workplace drug panels (SAMHSA-5, 10-panel) do not routinely screen for SARMs. Military testing has added some SARM panels. If your concern is an employer or probation test rather than sports, the probability of detection depends entirely on whether the specific panel orders a SARM assay.

What Are the Documented Safety Risks of SARMs?

The safety database for SARMs in humans is thin by the standards of approved drugs, but adverse events have been reported across several domains.

Liver toxicity. A 2020 case series in Annals of Internal Medicine described 3 patients presenting with cholestatic hepatitis after using ostarine or LGD-4033 purchased online. Bilirubin peaked above 20 mg/dL in one case; all three recovered after stopping the compound and receiving supportive care. [7]

Cardiovascular effects. The Basaria LGD-4033 Phase I trial showed dose-dependent reductions in HDL cholesterol of up to 40% from baseline, even at 1 mg/day. [5] Given that low HDL is an independent cardiovascular risk factor, this finding carries clinical significance for longer use periods.

Psychiatric effects. Case reports describe aggression, mood instability, and depression during and after SARM cycles, consistent with what is observed during anabolic steroid use. The mechanism is HPG axis dysregulation and fluctuating androgen levels.

Product purity. A 2017 JAMA Internal Medicine analysis of 44 products sold as SARMs found that only 52% actually contained a SARM, 39% contained an unapproved drug, and 25% contained substances not listed on the label. [12] Consumers therefore accept both the risks of SARMs and the risks of unknown adulterants.

How SARMs Compare to Supervised TRT for Body Composition

Testosterone replacement therapy (TRT) prescribed for confirmed hypogonadism (morning total testosterone consistently below 300 ng/dL by Endocrine Society criteria) is FDA-approved, covered by insurance in many plans, and supported by decades of safety and efficacy data. The 2018 Endocrine Society Clinical Practice Guideline recommends TRT for men with classic hypogonadism and states that testosterone therapy "increases lean body mass and reduces fat mass." [8]

In the Testosterone Trials (TTrials, N=790 men aged 65 and older with low testosterone), the Sexual Function Trial showed improvement in sexual desire and erectile function, while the Physical Function Trial showed a modest 1.57 kg improvement in lean mass over 12 months. [13] These gains are in older hypogonadal men using physician-prescribed testosterone gel. They are smaller than the gains seen in supraphysiologic testosterone studies because the dose targets physiologic replacement, not supra-physiologic enhancement.

SARMs, by contrast, are used at doses chosen by the user based on internet forums, sourced from vendors with no regulatory oversight, and without baseline bloodwork to establish whether HPG suppression or hepatic injury is occurring. For a patient who qualifies for TRT, supervised testosterone replacement offers a more favorable benefit-risk ratio than self-administered SARMs at every measurable dimension: legal standing, safety monitoring, and evidence base.

What the FDA and DEA Are Actually Doing About SARMs Now

Regulatory pressure on SARMs has increased since 2019. The FDA has sent warning letters to companies including Proven Peptides, Iron Mag Labs, and Enhanced Athlete, ordering them to stop selling SARMs for human consumption. In 2021, the FDA and FTC sent joint warning letters to seven companies. Several criminal prosecutions have followed: in 2021, a federal indictment in Georgia charged a SARMs distributor under the Federal Analog Act and misbranding provisions of the FDCA.

The 2023 FDA Modernization Act 2.0 did not address SARMs scheduling directly, but FDA's Center for Drug Evaluation and Research has stated it considers SARMs unapproved new drugs requiring an IND application for any human use. [1]

As of July 2025, the SARMs Control Act has not been re-introduced in the 119th Congress. However, the DEA retains authority to emergency-schedule compounds structurally similar to anabolic steroids under DASCA, which could apply to RAD-140 and LGD-4033 if enforcement priorities shift.